Menu
1-702-720-6310 info@microcapspecualtors.com

Three Biotechs Enter…One Biotech Gains – Barron’s


Barron’s

Three Biotechs Enter…One Biotech Gains
Barron’s
On gross:net, investors were increasingly aware of this issue, and as we discussed in our biotech previews, consensus modeling +5% QoQ growth for Otezla didn’t seem reasonable in light of CELG mgmt’s comments on Q1 call on Otezla: “expanded access …
Celgene Dips On $95 Million Lag In Psoriasis Sales, But Earnings TopInvestor’s Business Daily

all 112 news articles »

Search